RxDoctor Payments Data

Sandra Downey

Physician Assistant · Dallas, TXNPI 1184101081

Payments from drug & device makers

$3,299in general payments, 2019–2025

Across 151 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$431
  • Pfizer$422
  • Merck$344
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$296
  • Bayer$278
  • Actelion Pharmaceuticals US, Inc.$226
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$2006%
  • Food & beverage$3,09994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,299 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$1,669
Medicare patients
15
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$92,197
EntrestoSacubitril/Valsartan36$52,242
MultaqDronedarone Hcl18$31,659
XareltoRivaroxaban20$23,409
CorlanorIvabradine Hcl13$15,436
Metoprolol Succinate201$3,531
Ranolazine ErRanolazine22$2,424
Nebivolol Hcl14$1,231
Ezetimibe29$1,227
Rosuvastatin Calcium65$1,100
Bisoprolol Fumarate26$1,093
Carvedilol84$904
Nifedipine ErNifedipine28$855
Lisinopril83$769
Atorvastatin Calcium120$768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$422$92,19783 claims
NovartisEntresto$431$52,24236 claims
Sanofi-aventis U.S. LLCMultaq$214$31,65918 claims
Johnson & JohnsonXarelto$75$23,40920 claims
AmgenCorlanor$212$15,43613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →